Brunstein Claudio G, Setubal Daniela C, Wagner John E
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
Br J Haematol. 2007 Apr;137(1):20-35. doi: 10.1111/j.1365-2141.2007.06521.x.
Umbilical cord blood has become a valuable alternative source of haematopoietic stem cells for allogeneic transplantation. However, largely because of the impact of cell dose on engraftment, risk of transplant-related mortality and survival, progress in the field has been largely restricted to children. Nevertheless, substantial clinical experience with umbilical cord blood transplantation clearly establishes its safety and effectiveness in young patients with a variety of malignant and non-malignant diseases. Although less well established in adults, new strategies are now being explored to address the obstacle of cell dose. This article reviews the state of the art and future directions with umbilical cord blood as a source of haematopoietic stem cells for transplantation in both children and adults.
脐带血已成为异基因移植中造血干细胞的宝贵替代来源。然而，很大程度上由于细胞剂量对植入、移植相关死亡率和生存率的影响，该领域的进展主要局限于儿童。尽管如此，脐带血移植的大量临床经验清楚地证实了其在患有各种恶性和非恶性疾病的年轻患者中的安全性和有效性。虽然在成人中应用尚不完善，但目前正在探索新的策略来解决细胞剂量这一障碍。本文综述了以脐带血作为造血干细胞来源用于儿童和成人移植的最新进展及未来方向。
